Overall, 560 of the 675 children, or 83.0%, had an effective response at six months. The participants were aged 24 months or younger when combined treatment began and were treated during the study period of 2012–2025. Because every child in the development cohort had already been selected for combination therapy, the results do not compare propranolol with polidocanol or establish which treatment a child should receive.

Researchers addressed missing baseline data with 20 multiply imputed datasets. They used LASSO in repeated analyses across those imputations, including a 200-resample stability comparison, to evaluate candidate predictors. A final 10-predictor specification was then locked before a separate internal validation using 1,000 conditional bootstrap resamples. This separation meant that the final model was not altered after the validation assessment was initiated.

The locked Stable10 model incorporated lesion location, premature birth, age at the start of combined therapy, lesion depth, lesion type, baseline echocardiogram pattern, treatment pathway, maximum lesion diameter, lesion thickness and blood-flow grade. For the pooled, shrunken coefficient formula used in the accompanying calculator, the apparent area under the receiver operating characteristic curve, or AUC, was 0.920. The bootstrap optimism-corrected AUC was 0.896, with a conditional location-shifted 95% bootstrap interval of 0.886–0.926.

Measures of calibration also indicated agreement between model predictions and observed outcomes. The corrected Brier score was 0.095, with a 95% interval of 0.075–0.102. The calibration intercept was 0.023, with a 95% interval of −0.028 to 0.064, while the calibration slope was 0.949, with a 95% interval of 0.914–1.018. The model was designed to estimate a continuous probability of response at six months rather than classify children only into fixed response categories.

In a separate analysis of additional-injection burden across the full cohort of 675 children, investigators used robust Poisson regression. Surface elevation was associated with a higher rate of additional injections during the first six months. The adjusted incidence rate ratio was 1.27, with a 95% confidence interval of 1.01–1.58 and P = 0.039. The authors described this finding as exploratory; it is an association within the treated cohort and does not show that surface elevation caused additional injections or that changing treatment would reduce them.

The results support the model’s internal performance in the population used to develop it, but they do not establish how the calculator would perform in children treated at other hospitals, in different populations or under different treatment pathways. Internal validation evaluates whether the model retains its performance when tested within the development data; external validation is required to assess performance in independent settings and populations.

For now, the calculator should be regarded as a research tool rather than a routine clinical decision aid. The study’s central result is that a baseline model built from 10 child and lesion characteristics can estimate six-month response with good discrimination and calibration among children receiving the selected combination therapy. Whether those estimates remain accurate outside the development cohort remains an open question that requires prospective external evaluation.

Subject of Research: Internal validation of a six-month treatment-response prediction model for children with infantile hemangioma

Article Title: Development and internal validation of a prediction model for 6-month response in children with infantile hemangioma selected for propranolol and polidocanol injection

Article References: Liu, X., Sun, Y., Wang, Y., Zhang, Y., Mu, W., & Li, A. (2026). Development and internal validation of a prediction model for 6-month response in children with infantile hemangioma selected for propranolol and polidocanol injection. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07874-4

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07874-4

Keywords: infantile hemangioma, prediction model, internal validation, propranolol, polidocanol, treatment response, pediatrics, lesion characteristics, injection burden, Development, internal, validation

The so-called beta blocker era began in 2008, when the cardiac drug propranolol was serendipitously found to shrink problematic hemangiomas, a discovery that transformed pediatric dermatology and vascular anomaly care almost overnight. Before propranolol became standard therapy, ulceration was reported in approximately fifteen to thirty percent of infants with hemangiomas. Widespread beta blocker use has driven that figure down to around eleven percent, and a recent retrospective cohort study found that only about five percent of propranolol-treated patients developed a new ulcer after starting treatment. These are genuine gains, but the review’s authors are emphatic that the complication has not been eliminated. Ulcers still develop before therapy begins, and, perhaps counterintuitively, some emerge or even worsen after propranolol has been started, a paradox that the researchers trace back to the underlying biology of the tumors themselves.

Understanding who is at risk has become considerably more precise. Ulceration shows a strong predilection for specific lesion types and anatomical locations. Rapidly proliferating, large, superficial, mixed, and segmental lesions are the most vulnerable, particularly when they involve the lips, neck, diaper area, perineum, anogenital region, or skin folds, where friction, moisture, and mechanical stress relentlessly assault a fragile epidermal barrier. The numbers from referral cohorts are striking. In a multicenter study of 435 anogenital hemangiomas, more than half, 53.3 percent, developed ulceration, rising to 71.7 percent among segmental or partially segmental lesions. Among 69 lip hemangiomas, 53.6 percent ulcerated. Multivariate analyses have quantified these risks further: segmental morphology roughly doubled the odds of ulceration in anogenital lesions, mixed type more than tripled them, and a lower-lip location increased the odds more than eightfold compared with upper-lip disease.

Crucially, the review highlights that risk factors for ulceration after propranolol initiation may not mirror those before treatment. In a cohort of propranolol-treated infants, mixed, indeterminate, and segmental hemangiomas were independent risk factors for new ulcers, with segmental lesions carrying an odds ratio exceeding twenty-two, while trunk and extremity locations appeared protective. This distinction matters clinically, because it means that even after systemic beta blocker therapy has begun, physicians cannot assume that a lesion’s morphology has stopped mattering. Girls account for roughly three quarters of ulcerated cases, consistent with the overall female predominance of hemangiomas, though the evidence does not support sex as an independent risk factor once other variables are accounted for. Prematurity, black ethnicity, and lower socioeconomic status have also been linked to ulceration, though the latter associations may partly reflect delayed diagnosis and unequal access to specialist care rather than biology alone.

The pathogenesis of ulceration, the review argues, is best understood not as a simple surface wound but as a dynamic, multifactorial process rooted in tumor biology. During the rapid proliferative phase, the metabolic demands of tumor cells, endothelial cells, and stromal cells surge, yet the newly formed vessels feeding the lesion are structurally immature and often fail to deliver adequate oxygen. This supply-demand mismatch leaves the superficial tissues relatively hypoxic, priming them for necrosis and epidermal breakdown. One of the most clinically valuable insights concerns early white discoloration of the lesion, which histological studies have linked to upper dermal fibrosis and matrix remodeling. This pallor is now recognized as an important warning sign of impending ulceration, giving clinicians a window to intervene before the skin actually breaks down.

The review also delivers a sobering technical caveat about imaging. Conventional Doppler ultrasound, the workhorse for characterizing hemangiomas and monitoring treatment response, measures macroscopic blood flow rather than capillary perfusion or oxygen diffusion at the epidermal-dermal interface. Preserved intralesional flow on Doppler therefore does not exclude focal superficial ischemia, meaning that no Doppler parameter has been validated to predict ulceration. Ultrasound should complement, not replace, clinical risk assessment based on lesion morphology, location, growth pattern, and early whitening. In the diaper area, the authors describe a double-hit mechanism: intrinsic proliferative hypoxia weakens the barrier, while moisture, maceration, pH changes, enzymatic irritation, and microbial colonization continuously erode the stratum corneum, pushing the lesion from early ischemic whitening toward overt ulceration.

Once an ulcer has formed, molecular mechanisms may conspire to keep it open. Relative tissue hypoxia stabilizes hypoxia-inducible factor-1 alpha, drives vascular endothelial growth factor signaling that produces functionally immature vessels, and increases matrix metalloproteinase activity. The resulting degradation of the extracellular matrix and basement membrane amplifies barrier failure, promoting ulcer persistence, delayed healing, and scarring. The authors caution that direct evidence for this protease-inhibitor imbalance in hemangioma ulcers specifically remains limited, borrowing plausibility from the chronic wound literature, but the framework offers a coherent explanation for why some ulcers heal slowly, become infected, and leave prominent scars. Timing is also characteristic: approximately eighty to ninety-five percent of ulcers develop during the proliferative phase, most often between two and four months of age, with more than half occurring within the first four months of life.

On the treatment side, the review’s central message is that no single modality suffices. Oral propranolol remains the mainstay of systemic therapy, controlling tumor proliferation, relieving pain, and promoting wound healing, with reported median healing times of roughly six to seven weeks in multicenter cohorts. Yet the optimal dose remains unresolved. One analysis found that doses of one milligram per kilogram per day or less were associated with shorter healing times, while a prospective study using two milligrams per kilogram per day reported complete healing in a mean of 5.5 weeks. Because dose selection is confounded by age, ulcer severity, and clinician preference, the authors suggest that a cautious initial dose with individualized titration may be reasonable, while stressing that the question demands proper randomized trials. A small number of children experience worsening ulcers after propranolol initiation or escalation, particularly when tissue ischemia or barrier damage predates treatment, so dynamic reassessment during therapy is essential.

Around this systemic backbone, the review maps the supporting cast. Wound care, gentle cleansing, nonadherent dressings, barrier creams, hydrocolloids, and antimicrobial dressings, forms the cornerstone of management, though no single method has proven superior, and caregivers need clear written instructions and warning signs that warrant medical review. Pain should be assessed at every visit with age-appropriate behavioral scales, with acetaminophen preferred for systemic analgesia and topical lidocaine used sparingly under supervision. Topical timolol offers a local option for small, superficial, focal ulcers, with reported healing times ranging from about nineteen days in randomized study conditions to five weeks in broader cohorts. Pulsed dye laser therapy, which targets superficial vascular components, can accelerate healing of painful or bleeding superficial ulcers, with one randomized trial reporting a mean healing time of 19.22 days, but it is not effective for all lesions and should not be considered routine first-line therapy. For moderate to severe or complex ulcers, multimodal combinations are often necessary, though claims of synergy between propranolol and laser therapy rest on small, uncontrolled series.

Perhaps the review’s most important contribution is conceptual: ulcerated infantile hemangioma should be judged not by the size of the wound alone but across multiple dimensions, including pain, infection, anatomical function, healing trajectory, caregiver burden, and long-term cosmetic outcome. Even small ulcers under five square centimeters can devastate feeding, sleep, and diaper care when they sit on the lip, perineum, or periocular region. No validated ulceration-specific scoring system yet exists, and the authors call for prospective multicenter studies to standardize severity definitions, refine risk-stratified treatment algorithms, and test emerging therapies such as atenolol, nadolol, dual-wavelength lasers, and topical brimonidine-timolol combinations. Their proposed framework, connecting quantitative risk recognition, dynamic pathogenesis, lesion-directed therapy, wound care, and family-centered outcomes, aims to shift practice from reactive wound management toward earlier, individualized, multidisciplinary care. For the infants and families who bear the burden of this painful complication, that shift cannot come soon enough.

Subject of Research: Ulcerated infantile hemangioma: risk factors, pathogenesis, and management in the beta-blocker era

Article Title: Ulcerated infantile hemangioma in the β-blocker era: recent advances

Article References: Zhang, K.-Z., Guo, R.-M., Qiu, T., Yang, M., & Ji, Y. (2026). Ulcerated infantile hemangioma in the β-blocker era: recent advances. World Journal of Pediatrics. https://doi.org/10.1007/s12519-026-01101-x

Image Credits: AI Generated

DOI: 10.1007/s12519-026-01101-x

Keywords: infantile hemangioma, ulceration, propranolol, beta blockers, pediatric dermatology, wound care, topical timolol, pulsed dye laser, PHACE syndrome, LUMBAR syndrome, risk stratification, tissue hypoxia

To understand why this case matters, it helps to know how vascular tumors of infancy are classified. Hemangiomas are the most common vascular tumors of infancy, and clinicians broadly divide them into infantile hemangiomas, which typically appear after birth and grow during early infancy, and congenital hemangiomas, which are fully formed by the time a baby is born. Congenital hemangiomas are themselves split into three behavioral categories: rapidly involuting congenital hemangiomas, which regress quickly after birth; non-involuting congenital hemangiomas, which persist indefinitely; and partially involuting congenital hemangiomas, which shrink somewhat but never disappear entirely. This three-way classification, formalized in influential work by Mulliken and Enjolras, reflects the fact that these tumors behave in fundamentally different ways despite looking superficially similar under the microscope.

The genetic underpinnings of congenital hemangiomas have become clearer in the past decade. Researchers have identified somatic activating mutations in the GNAQ and GNA11 genes in these tumors — alterations that occur in the tumor tissue itself rather than being inherited, and that drive the abnormal proliferation of blood vessel cells. This molecular signature distinguishes congenital hemangiomas from infantile hemangiomas, which follow a different biological program altogether. One of the classic diagnostic markers separating the two is GLUT1, a glucose transporter protein that is abundantly expressed in infantile hemangiomas but characteristically absent in congenital ones. Immunohistochemical staining for GLUT1, first described as a diagnostic marker for juvenile hemangiomas in landmark work published in 2000, remains a cornerstone of daily practice in distinguishing cutaneous vascular anomalies.

Most congenital hemangiomas appear on the skin and soft tissues of the head and neck or around the joints of the extremities — the periarticular regions. A RICH on a scalp or a knee is unusual enough; a RICH inside the brain, in the suprasellar region, is a genuine medical rarity. The suprasellar region is one of the most crowded and consequential addresses in the human brain. It houses the pituitary gland, the optic chiasm, the hypothalamus, and the circle of Willis, the arterial ring that supplies blood to much of the cerebrum. Tumors in this location — whether congenital craniopharyngiomas, hypothalamic hamartomas, or other lesions — can threaten vision, hormone regulation, and core metabolic functions, and they often demand delicate neurosurgical intervention. The prospect of a vascular tumor growing there before birth is the kind of finding that sets off immediate alarm bells in any fetal imaging suite.

That is precisely what makes the new report so valuable. The lesion was first detected on prenatal ultrasound, the workhorse of fetal surveillance, and then further characterized with fetal MRI, which offers superior soft-tissue contrast and can help differentiate vascular lesions from other fetal brain tumors. Fetal brain tumors themselves are exceedingly rare, and imaging them well is a technical challenge; a dedicated review of fetal brain tumor imaging published in Pediatric Radiology in 2020 underscored how difficult it can be to pin down a precise prenatal diagnosis. In this case, the imaging features and clinical course pointed toward a RICH, and the diagnosis was confirmed by the tumor’s behavior after birth: serial postnatal ultrasound and MRI demonstrated rapid interval regression, the hallmark of the rapidly involuting subtype.

The natural history of RICH tumors is what gives this case its happy ending. These tumors are fully grown at birth — they do not exhibit the postnatal proliferation phase that defines infantile hemangiomas — and then they begin to shrink, often dramatically, during the first months of life. Many resolve completely, sometimes leaving behind only a subtle patch of atrophic skin or residual telangiectasias when they occur on the skin. The speed of involution can be striking, which is how the subtype earned its name. But the behavior of a RICH in the brain is far less well charted than its cutaneous counterpart, simply because so few intracranial cases have been reported. Prior reports have described RICH lesions of the skull and the hand, and one team documented prenatal diagnosis and postnatal follow-up of a RICH in this same journal more than a decade ago, but suprasellar examples remain vanishingly scarce.

The clinical stakes of such a diagnosis are considerable. Congenital hemangiomas are usually benign and self-limited, but they are not always harmless. Rare catastrophic cases have been described in which congenital hemangiomas caused severe coagulopathy — a consumption of clotting factors by the tumor’s high-flow vasculature — leading to fatal cardiac failure in newborns. High-flow vascular lesions in the brain carry additional risks, including hemorrhage and mass effect on critical structures. For families and clinicians facing a prenatal diagnosis of a suprasellar mass, the differential diagnosis includes lesions with far grimmer prognoses, and the temptation toward aggressive intervention can be strong. A documented case in which watchful waiting was rewarded by spontaneous, imaging-confirmed regression provides a crucial data point: not every prenatal brain mass is a surgical emergency, and accurate diagnosis can spare an infant invasive procedures.

That said, the report also implicitly acknowledges that not all congenital hemangiomas can be left alone. When these tumors cause serious complications, medical therapy has entered the picture in recent years. Sirolimus, an mTOR inhibitor better known as an immunosuppressant, has emerged as a treatment option for problematic vascular anomalies, and a 2026 report in Pediatric Blood & Cancer described the successful management of a refractory congenital hemangioma with sirolimus in a neonate. The decision matrix for a neonatal vascular tumor thus spans a spectrum from simple observation to pharmacotherapy to, in select cases, surgery — and the choice hinges on accurate subtype classification, which is exactly where detailed imaging documentation like that in this new case report earns its keep.

For the radiology community, the case adds a rare entry to the atlas of fetal and neonatal intracranial vascular tumors, complete with the kind of longitudinal imaging follow-up that textbooks crave. For the broader public, it is a reminder of how much the prenatal imaging revolution has changed medicine: a tumor invisible to any previous generation of doctors is now spotted on ultrasound before a baby takes its first breath, characterized by MRI in utero, and tracked noninvasively as it resolves. The researchers reported no competing interests, obtained written informed consent from the child’s parents, and noted that institutional review board approval was not required for this single case report under institutional policies. The authors — Noman Khan, Rafaela Minguetti, Alexandra J. Borst, Kimberly M. Hamilton, and Carolina V. Guimaraes — frame the contribution around the clinical course and imaging features of the lesion, offering colleagues worldwide a template for recognizing a diagnosis that most will encounter only once, if ever, in their careers.

Behind the technical narrative lies a genuinely moving human story: parents who learned before birth that their child had a mass in one of the most delicate regions of the brain, and who then watched, scan by scan, as that mass melted away on its own. Medicine’s growing ability to distinguish tumors that threaten from tumors that retreat — using imaging signatures, immunohistochemical markers like GLUT1, and now somatic genetics — is quietly transforming outcomes for infants like this one. In an era when the word tumor triggers instinctive dread, this suprasellar RICH stands as a counterexample: a lesion that arrived fully formed, announced itself on fetal MRI, and then, true to its name, vanished in a rush — leaving behind only images, data, and a rare lesson in the power of knowing when to do nothing at all.

Subject of Research: A rare case of rapidly involuting congenital hemangioma in the fetal suprasellar brain region documented by prenatal and postnatal imaging

Article Title: Rapidly involuting congenital hemangioma of the suprasellar region

Article References: Khan, N., Minguetti, R., Borst, A. J., Hamilton, K. M., & Guimaraes, C. V. (2026). Rapidly involuting congenital hemangioma of the suprasellar region. Pediatric Radiology. https://doi.org/10.1007/s00247-026-06780-2

Image Credits: AI Generated

DOI: 10.1007/s00247-026-06780-2

Keywords: congenital hemangioma, RICH, suprasellar region, fetal MRI, prenatal diagnosis, pediatric radiology, vascular tumors, GLUT1, GNAQ mutation, infantile hemangioma, spontaneous regression, neonatal imaging